Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05245071
Title Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.